Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion

22 May 2018

Abstract excerpt

Immune checkpoint blockade therapies (ICBTs) targeting programmed cell death 1 (PD-1) and its ligand programmed death ligand-1 (PD-L1/B7-H1/CD274) have exhibited momentous clinical benefits and durable responses in multiple tumor types. However, primary resistance is found in considerable number of cancer patients, and most responders eventually develop acquired resistance to ICBT. To tackle these challenges, it...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to CAR-T cell therapy research
Share to Peptidase Inhibition and Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29910728
DOI: 10.3389/fphar.2018.00536

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune EvasionPMID 29910728Read ↗

Complex regulatory network of programmed death-ligand 1 in cancer: Cancer immunomodulation from molecular mechanisms to clinical applicationsSemantic proximity Read ↗

PD-L1: expression regulationSemantic proximity Read ↗

Posttranslational regulatory mechanism of PD-L1 in cancers and associated opportunities for novel small-molecule therapeuticsSemantic proximity Read ↗

Programmed Death Ligand 1 Regulatory Crosstalk with Ubiquitination and Deubiquitination: Implications in Cancer ImmunotherapySemantic proximity Read ↗

Regulatory mechanisms of PD-1/PD-L1 in cancersSemantic proximity Read ↗

Recent Findings in the Regulation of Programmed Death Ligand 1 ExpressionSemantic proximity Read ↗

Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to TherapySemantic proximity Read ↗

Epigenetic modifications: Critical participants of the PD‑L1 regulatory mechanism in solid tumors (Review)Semantic proximity Read ↗

Research progress on the intrinsic non‑immune function of PD‑L1 in tumors (Review)Semantic proximity Read ↗

Role of tumor microenvironment in the regulation of PD‐L1: A novel role in resistance to cancer immunotherapySemantic proximity Read ↗

Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapySemantic proximity Read ↗

The Role of Oncogenes and Redox Signaling in the Regulation of PD-L1 in CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.